• 156,984,578 options exercised, raising $1.9M
• Remaining options lapsed, simplifying capital structure
• Cash balance strengthened to $6.3M ahead of Phase III interim results

Avecho Biotechnology Limited (ASX: AVE) announced the expiry of its listed options trading under ASX code AVEOA, which were exercisable at $0.012 each. Of the 2,167,130,063 AVEOA options on issue as of 30 April 2026, a total of 156,984,578 were exercised, raising approximately $1.9 million in cash (before costs). The remaining options lapsed, unexercised. The additional $1.9 million in cash further strengthens the company's existing cash balance of $4.4 million as of 31 March 2026, resulting in a proforma cash position of approximately $6.3 million. Avecho plans to use the additional proceeds to further progress licensing discussions following the planned Phase III interim analysis for its TPM-enhanced cannabidiol soft-gel capsule for the treatment of insomnia, which is expected in the first half of 2026. The company's CEO, Dr. Paul Gavin, commented that the exercise and expiry of these options represent a strong outcome, providing meaningful additional cash and a materially simplified capital structure, positioning the company in a significantly stronger financial position as it approaches the Phase III interim analysis results.

The company anticipates using the additional $1.9 million (before costs) from the option exercises to further progress licensing discussions following the planned Phase III interim analysis for its TPM-enhanced cannabidiol soft-gel capsule for the treatment of insomnia, which is expected in the first half of 2026.